Understanding the above pathophysiology behind the formation of F VIII inhibitors in MPN, throws open a question regarding the potential for JAK inhibitors, like ruxolitinib, pacritinib and momelotinib, in modulating the immune response and, thus, preventing the formation of inhibitors. The gene discussed is F8; the disease is myeloproliferative disorder.